HomeChugai Obtains Approval for Additional Indication of Rozlytrek (generic name: entrectinib) for ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Chugai Obtains Approval for Additional Indication of Rozlytrek (generic name: entrectinib) for ROS1 Fusion-Positive Non-Small Cell Lung Cancer

TOKYO, 21.02.2020